UK markets closed

Valbiotis SA (ALVAL.PA)

Paris - Paris Delayed price. Currency in EUR
Add to watchlist
3.6300+0.0500 (+1.40%)
At close: 05:35PM CET
Full screen
Previous close3.5800
Open3.6000
Bid0.0000 x 0
Ask0.0000 x 0
Day's range3.5600 - 3.7000
52-week range2.8200 - 7.5000
Volume24,866
Avg. volume33,669
Market cap57.275M
Beta (5Y monthly)-0.29
PE ratio (TTM)N/A
EPS (TTM)-0.8500
Earnings date29 Apr 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est10.10
  • Business Wire

    Valbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II/III Clinical Study on TOTUM•63: Proven Efficacy on the Main Risk Factor of Developing Type 2 Diabetes

    LA ROCHELLE, France, May 22, 2023--Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA/PME eligible) (Paris:ALVAL), a commercially oriented Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces the large success of the REVERSE-IT Phase II/III clinical study on TOTUM•63. Conducted in 636 prediabetic and untreated type 2 diabetic patients (early stage), this international, multicentric, randomized and pla

  • Business Wire

    Valbiotis – Combined Annual Shareholders General Meeting held on May 2, 2023

    LA ROCHELLE, France, May 03, 2023--Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a commercially oriented Research and Development company, committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces its Combined Annual Shareholders Meeting was held on May 2, 2023 at Espace Encan, La Rochelle, under the chairmanship of Sébastien PELTIER, Chairman of the Board of Directors.

  • Business Wire

    Valbiotis announces the release of the Universal Registration Document

    LA ROCHELLE, France, April 26, 2023--Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible) (Paris:ALVAL), a commercially oriented Research and Development company, committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces that its Universal Registration Document was filed to the French Financial Markets Regulator (AMF) April 26, 2023.